课题基金 / 基金详情

Investigation of Gastrointestinal Adverse Events of Brand Versus Generic Osteoporosis Medications: Merits and Limitations of Different Non-Experimental Research Methods

Investigation of Gastrointestinal Adverse Events of Brand Versus Generic Osteoporosis Medications: Merits and Limitations of Different Non-Experimental Research Methods
品牌与仿制药骨质疏松症药物胃肠道不良事件的调查：不同非实验研究方法的优点和局限性
批准号：
404054
负责人：
Hayes Kaleen N
金额：
$7.65万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-10-01 至 2021-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=404054&lang=en
关键词：
Comparative Effectiveness Research Drug Safety Epidemiologic Methods Gastrointestinal Health Osteoporosis Pharmacoepidemiology Pharmacovigilance

项目摘要

项目成果

Hayes Kaleen N的其他基金

相似基金

相关文献

中文摘要
翻译
骨质疏松症是一种易发生骨折的骨质疏松症。超过200万加拿大人患有骨质疏松症。双膦酸盐（BP）类药物目前广泛用于骨质疏松症的治疗和预防。
英文摘要
Osteoporosis is a condition of brittle bone which makes patients susceptible to fractures. Over 2 million Canadians are affected by osteoporosis. The bisphosphonate (BP) class of medications is widely used today for osteoporosis treatment and prevention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fracture risk of sodium-glucose co-transporter 2 inhibitor therapy in high-risk older adults: population-based studies to establish comparative safety
海外基金